ACell MatriStem® Technology Ranks Highest in Constructive Remodeling


Columbia, MD – (May 15, 2013) – ACell, Inc., a leading developer of next-generation regenerative medicine products, announced today that its MatriStem medical devices demonstrate the highest constructive remodeling response in a recent study comparing 14 extracellular matrices (ECM) designed to aid in surgical procedures. The study, “Macrophage phenotype as a predictor of constructive remodeling following the implantation of biologically derived surgical mesh materials,” by Bryan Brown and other researchers of the McGowan Institute for Regenerative Medicine, University of Pittsburgh, PA was published in the July 2012 issue of Acta Biomaterialia.1

Constructive remodeling is healing through the creation of site-appropriate new tissue, which is in contrast to scarring, the typical healing response characterized by hard fibrous tissue without blood supply or nerves. Healing by constructive remodeling is clinically and functionally superior because it results in healthy viable tissue that most closely resembles the area that is missing or damaged. In the study, constructive remodeling was assessed by the presence of the M2 macrophage phenotype, while scarring was assessed by the presence of the M1 macrophage phenotype. These cells have been shown to play distinct roles in tissue remodeling following injury.

In the preclinical study, MatriStem elicited an early strong constructive remodeling response, with increased numbers of M2 macrophages and higher ratios of M2:M1macrophages, which led to the most favorable host remodeling response among all studied matrices at both 14 and 35 days post-surgery. This response was determined through specific cell staining and was correlated to long-term tissue remodeling outcomes.

“Clinicians that use MatriStem have seen unparalleled results in wound care and across various surgical procedures due to its ability to promote healing with healthy, natural tissue,” said Rodney Bosley, ACell President & COO. “The published scientific evidence supports the reason for these superior results, by demonstrating that the strong early M2macrophage response associated with MatriStem positively impacts the final healing outcome.”

About ACell

ACell, Inc. is a leading developer, manufacturer and marketer of next-generation regenerative medicine products. Its products are cleared for a variety of indications and are marketed under the brand name “MatriStem.” A privately held Company, Acell produces MatriStem in its manufacturing facilities and markets its products to physicians in the U.S. through a national direct sales force. For more information, call (800) 826-2926 or visit www.acell.com.

About MatriStem

MatriStem Products consist of porcine-derived extracellular matrix (ECM) that maintain and support a healing environment through constructive remodeling, and are available in particle and sheet forms by prescription only. These devices, trademarked as MatriStem, are appropriate for acute wounds, chronic wounds and various surgical procedures. All MatriStem devices are made in the USA. Refer to IFU supplied with each device for indications, contraindications, and precautions.

1BN Brown et a. Acta Biomaterialia 8 (2012) 978–987, viawww.sciencedirect.com/science/article/pii/S1742706112000918

Download a PDF of this article

Return to News